New insights into HL biology
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.
Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.
Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.
High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.
Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…
Professor Sagar Lonial (Emory University School of Medicine), Professor Gareth Morgan (UAMS Myeloma Institute) and Professor Graham Jackson (Newcastle) discuss what 2017 might hold for patients and the management of myeloma and… read more.
Article written by Tom Collins. Interview by Esther Drain. With technology that allows clinicians to determine minimal residual disease negativity down to the 10-6 level, the word “cure” hangs… read more.
Professor Mohamad Mohty (Paris), Professor Sagar Lonial (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.
Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.